|
|
|
|
|
|
|||
Canterbury Medical Research Foundation grants awarded.Monday 5 October 2009 Health researchers at the University of Otago, Christchurch have been awarded nearly $357,000 in project grants by the Canterbury Medical Research Foundation as part of its annual grant round for 2009. All these studies rely on contributions from the CMRF and its members who have been supporting health research in Canterbury for nearly fifty years. More details can be found at www.cmrf.org.nz Associate Professor Andrew Day. Paediatric Gastroenterology ($62,756). Investigating influences on the expression of antimicrobial peptides on epithelial cells in inflammatory bowel disease. Canterbury has a high rate of IBD compared to the rest of the world. Dr Gabi Dachs. Angiogenesis and Cancer Research Group ($56,992). Investigate the impact of obesity on treatment response and prognosis in colorectal cancer. One in five New Zealand adults are obese and we have one of the highest rates in the world of colorectal cancer. Does obesity reduce the effectiveness of chemotherapy in colorectal cancer patients? Dr Lisa Stamp. Rheumatology Immunology Research Group ($42,147). Investigate the extent to which treatment of gout with allopurinol alongside the use of blood pressure medication, frusemide, has a negative impact on the management of this disease by increasing uric acid and oxypurinol in the blood. Dr Claire Dowson. General Practice Research Group. ($66,206). Determine the effect of long term use of SSRI antidepressants on cognitive and behavioural functioning of previously depressed, but currently well people. Sheree Gibb. Psychological Medicine. ($54,613). Research the use of an innovative approach to preventing suicidal behaviour through the use of daily text messaging. This pilot study of 50 people will examine the use of daily supportive text messaging to people who have presented to the Emergency Department following a suicide attempt. Dr Michael MacAskill. Department of Medicine ($74,350). Investigate whether advanced MRI scans and eye movement measurements are effective markers of progression in Parkinson’s disease. For further information contact: Associate Professor Andrew Day Virginia Irvine For a list of Otago experts available for media comment, please go to:
|
|
||
